CTRI/2010/091/002813已完成4 期
A prospective, multicentre, open-label, single armobservational study of Concor® treatment in Asian patientswith Essential Hypertension
Merck Pte Ltd3 International Business Park #02-01Nordic European CentreSingapore 6099270 个研究点目标入组 1,000 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 1,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patient aged 18 years old and above
- •Patient diagnosed with essential hypertension
- •Patient has been prescribed Concor® treatment but may or may not have commenced
- •treatment in the last 2 weeks (from the date of signed informed consent)
- •Patient has one of the following medical history prior to Concor® treatment
- •? Newly diagnosed with essential hypertension with repeated blood pressure
- •measurements of > 140/90, or
- •? Current or preceding anti-hypertensive therapy does not result in adequate
- •BP control, which requires either the addition of Concor® to the currently
- •prescribed treatment or a change of treatment to Concor®, or
- •? Experiences adverse reaction with his current or preceding antihypertensive
- •Patient has a HR > 70 at baseline (before starting Concor treatment)
- •Patient is regularly followed-up by/monitored by the investigator for essential
- •hypertension
- •Patient from whom a written informed consent has been obtained
排除标准
- •completed >2 weeks of Concor® treatment
- •acute heart failure or during episodes of heart failure decompensation requiring i.v.
- •inotropic therapy
- •cardiogenic shock
- •second or third degree AV block (without a pacemaker)
- •sick sinus syndrome
- •sinoatrial block
- •HR < 70 at baseline (before starting Concor treatment)
- •symptomatic bradycardia
- •currently on HR lowering treatment (for example verapamil, diltiazem, etc.)
- •symptomatic hypotension
- •severe bronchial asthma or severe chronic obstructive pulmonary disease
- •severe forms of peripheral arterial occlusive disease or severe forms of Raynaud's
- •untreated phaeochromocytoma
- •metabolic acidosis
- •hypersensitivity to Concor® or to any of the excipients. Any contraindication to
- •Concor® according to SmPC
研究者
相似试验
已完成
3 期
Trial to evaluate 3mg dose of Covid Vaccine of Cadila healthcare LimitedCTRI/2021/10/037137Cadila Healthcare Limited3,000
进行中（未招募）
1 期
Triumeq As an Integrase Single Tablet Regimen in People with HIV who Inject DrugsHuman Immunodeficiency Virus (HIV) infectionEUCTR2016-000087-42-IEniversity College Dublin50
已完成
Unknown
A clinical trial to evaluate the efficacy and safety of CareSens Air, a continuous glucose monitor, in adult patients with diabetes.Endocrine, nutritional and metabolic diseasesKCT0009215i-sens85
未知
3 期
Bosentan DDigital ulcers associated with systemic sclerosisJPRN-jRCT2080222130Actelion Pharmaceuticals Japan Ltd.20
进行中（未招募）
2 期
A Japanese Phase 2 study of 177Lu-PSMA-617 in participants with PSMA(+) mCRPCProstate CancerJPRN-jRCT2041210123Kazuyuki Suzuki28